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Protein C is a physiological anticoagulant factor and has 
been implicated in the pathogenesis of sepsis for many 
years. In the previous issue of Critical Care, Shorr and 
colleagues [1] add to our knowledge of the role of protein 
C in sepsis by presenting data from the RESPOND 
(Research Evaluating Serial Protein C Levels in Severe 
Sepsis Patients on Drotrecogin Alfa [Activated]) study, 
which demonstrates that administration of recombinant 
human activated protein C may modulate protein C 
levels and thereby potentially aﬀ  ect outcome in patients 
with severe sepsis. In 40% to 60% of patients with severe 
sepsis, plasma levels of protein C are low or very low 
because of impaired synthesis, consumption, and degra-
da  tion by proteolytic enzymes, such as neutrophil 
elastase [2,3]. Several studies point to the fact that the 
plasma level of protein C may be regarded as a strong 
predictor for the outcome in sepsis, and early improve-
ment in protein C levels strongly correlates with survival 
[4-6]. Apart from being a relevant biomarker, protein C is 
likely to be involved in the pathogenesis of sepsis. Th  e 
most typical example is meningococcal septicemia, in 
which very low plasma levels of protein C play a pivotal 
role in the occurrence of purpura fulminans [7]. In 
addition, transgenic mice show that deﬁ  ciency of protein C 
in sepsis is associated with enhanced inﬂ  ammatory activity 
[8]. Also, restoration of low protein C levels in septic 
baboons resulted in an amelioration of coagulopathy and 
reduced mortality [9]. Hence, there is ample evidence that 
increasing protein C levels in patients with sepsis could 
signiﬁ  cantly improve clinical outcome.
Shorr and colleagues show that the eﬀ  ect of variable 
dose regimens of recombinant human activated protein 
C can achieve this therapeutic goal. Patients who were 
randomly assigned to a strategy in which administration 
of recombinant human activated protein C was adjusted 
to their endogenous protein C levels – and who thereby 
sometimes received higher doses of recombinant human 
activated protein C (that is, 30 or 36 μg/kg per hour 
compared with the usual dose of 24 μg/kg per hour) and 
for a longer duration – achieved 7% higher levels of 
protein C as compared with conventional treatment. 
Remarkably, the authors’ results conﬁ  rmed the ﬁ  nding 
that normalization of protein C levels within 7 days had a 
major impact on mortality (10.3% in patients with 
normalized protein C levels compared with 32.0% in 
patients who did not normalize).
One of the strengths of the study by Shorr and 
colleagues is that it is the ﬁ   rst major clinical study 
investigating diﬀ   erential doses of recombinant human 
activated protein C. It is fair to say that dose-ﬁ  nding 
studies with recombinant human activated protein C are 
quite limited and that the currently used dose of 24 μg/kg 
per hour has been based on a plateau eﬀ  ect on D-dimer 
levels in a single phase II clinical trial [10]. It may well be 
that some patients with severe sepsis may need higher 
doses of activated protein C concentrate and for a 
duration longer than the standard 4-day schedule. Th  e 
study by Shorr and colleagues demonstrates that this is 
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cations during the infusion period. As major bleeding is a 
concern in patients with severe sepsis and as recombinant 
human activated protein C has been shown to signiﬁ  -
cantly (albeit, in absolute terms, very modestly) increase 
this risk [11], it is reassuring that the studied dose 
regimens in the RESPOND study did not clearly increase 
the bleeding rate.
Rather than intensifying or prolonging the treatment 
with activated protein C, many clinicians have adopted 
the practice of terminating the administration of 
recombinant human activated protein C in patients who 
are admitted with severe sepsis but who demonstrate a 
rapid and signiﬁ   cant improvement in their clinical 
condition. Although this seems to be a logical and cost-
conscious measure, we need to realize that this practice is 
not supported by sound clinical trial data.
A limitation of the study by Shorr and colleagues is that 
focusing on zymogen protein C levels may ignore the fact 
that, in patients with severe sepsis, protein C activation 
may be markedly impaired. Indeed, a signiﬁ  cant down-
regulation of thrombomodulin, caused by proinﬂ  amma-
tory cytokines such as tumor necrosis factor-alpha and 
interleukin-1, may occur in patients with severe sepsis, 
resulting in diminished protein C activation [2,12]. It may 
well be that directly administering activated protein C 
will overcome this impaired activation and that plasma 
protein C levels will act as merely an easy-to-measure 
biomarker to guide this treatment. To further explore this 
issue, it would be interesting to perform a head-to-head 
comparison between administration of recombinant 
human activated protein C and zymogen protein C 
concentrate in patients with severe sepsis, looking at 
restoration of plasma levels of protein C but also at 
clinically relevant outcomes, such as organ dysfunction 
and mortality.
In conclusion, the RESPOND study shows that a 
diﬀ   erential approach to the administration of recom-
binant human activated protein C may result in a more 
eﬀ  ective normalization of protein C levels. It is tempting 
to speculate on the translation of these ﬁ  ndings to better 
treatment outcome in patients with severe sepsis, but we 
need additional clinical studies that would demonstrate 
such an eﬀ  ect. In the meantime, it is clear that, in regard 
to activated protein C treatment in patients with sepsis, 
one size apparently does not ﬁ  t all.
Abbreviation
RESPOND, Research Evaluating Serial Protein C Levels in Severe Sepsis Patients 
on Drotrecogin Alfa (Activated).
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